Long‐term BP control and vascular health in patients with hyperaldosteronism treated with low‐dose, amiloride‐based therapy-Reference-Cited by-同舟云学术

Long‐term BP control and vascular health in patients with hyperaldosteronism treated with low‐dose, amiloride‐based therapy

Published:2019-06-06 Issue:7 Volume:21 Page:922-928
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J Clin Hypertens

Author:

Izzo Joseph L.¹²^ORCID,Hong Michael¹²,Hussain Tanveer¹²,Osmond Peter J.¹²

Affiliation:

1. Department of Medicine, Jacobs School of Medicine University at Buffalo Buffalo New York

2. Erie County Medical Center Buffalo New York

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.13567

Reference55 articles.

1. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population‐based cohort;Calhoun DA;Hypertension,1979

2. Pathogenesis of salt sensitivity of blood pressure

3. Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension;Pimenta E;Hypertension (Dallas, Tex,1979

4. Medical Management of Aldosterone-Producing Adenomas

5. Cardiovascular complications in patients with primary aldosteronism

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline;European Journal of Endocrinology;2024-03-30

2. Study of Amiloride Binding to Human Serum Albumin: Insights from Thermodynamic, Spectroscopic, and Molecular Docking Investigations;Molecules;2023-11-21

3. Redefining primary hyperaldosteronism as “The Syndrome of Inappropriate Aldosterone Secretion (SIALDS)”: A common but unrecognized cause of hypertension;The Journal of Clinical Hypertension;2023-10-25

4. Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1;Hypertension;2023-07

5. Impact of Primary Aldosteronism in Resistant Hypertension;Current Hypertension Reports;2022-04-21